1-10 of 10
Boris V. Afanasiev
Close
Sort by
Journal Articles

Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

Nicolaus Kröger, MD, Ronald Brand, PhD, Dietger Niederwieser, MD, Uwe Platzbecker, MD, Kai Hübel, MD, Thomas Weber, MD, Marie Robin, MD PhD, Matthias Stelljes, MD, Boris V Afanasiev, MD, Dominik Heim, MD, Giorgio Lambertenghi Deliliers, MD, Francesco Onida, MD, Peter Dreger, MD, Massimo Pini, MD, Stefano Guidi, Liisa Volin, MD, Martin Gramatzki, MD, Wolfgang A. Bethge, MD, Xavier Poire, MD, Guido Kobbe, MD, Marleen van Os, Simona Iacobelli, Theo de Witte, MD
Journal: Blood
Blood (2014) 124 (21): 320.
https://doi.org/10.1182/blood.V124.21.320.320
Published: 2014
Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Annika Dufour, Stefan K Bohlander, Evelyn Zellmeier, Gudrun Mellert, Karsten Spiekermann, MD, Stephanie Schneider, PhD, Purvi Kakadia, Wolfgang Hiddemann, PhD, Jan Braess, Sim Truong, Nancy Patten, Lin Wu, Galina Salogub, Philippe Solal-Celigny, Anna Dmoszynska, Tadeusz Robak, Boris V Afanasiev, Marco Montillo, John Catalano, MBBS FRACP FRCPA, Christian H. Geisler, David Dornan, Ming Lin, Ru-Fang Yeh, Martin Weisser, Guillemette Duchateau-Nguyen, Giuseppe Palermo
Journal: Blood
Blood (2011) 118 (21): 2445.
https://doi.org/10.1182/blood.V118.21.2445.2445
Published: 2011
Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Annika Dufour, PhD, Stefan K Bohlander, Evelyn Zellmeier, Gudrun Mellert, Karsten Spiekermann, MD, Stephanie Schneider, PhD, Purvi Kakadia, Wolfgang Hiddemann, PhD, Jan Braess, Sim Truong, Nancy Patten, Lin Wu, Galina Salogub, Philippe Solal-Celigny, Anna Dmoszynska, Tadeusz Robak, Boris V Afanasiev, Marco Montillo, John Catalano, MBBS FRACP FRCPA, Christian H. Geisler, David Dornan, Ming Lin, Ru-Fang Yeh, Martin Weisser, Guillemette Duchateau-Nguyen, Giuseppe Palermo
Journal: Blood
Blood (2011) 118 (21): 3521.
https://doi.org/10.1182/blood.V118.21.3521.3521
Published: 2011
Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Annika Dufour, MD, S. K Bohlander, PhD, Karsten Spiekermann, MD, Stephanie Schneider, Jan Braess, MD, Purvi Kakadiya, Kirsten E Mundt, PhD, Helen Smith, Ming Lin, PhD, Martin Barrett, PhD, Deborah Hurst, MD, Anna Dmoszynska, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Boris V Afanasiev, MD, John Catalano, MBBS, FRACP, FRCPA, Marco Montillo, Christian H. Geisler, MD, Sergey I Moiseev, MD, Philippe Solal-Celigny, MD, Tadeusz Robak, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2010) 116 (21): 1390.
https://doi.org/10.1182/blood.V116.21.1390.1390
Published: 2010
Journal Articles

Effect of FCGR2A and FCGR3A variants on CLL outcome

David Dornan, Olivia Spleiss, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, Annika Dufour, Jianguo Zhi, Tadeusz Robak, Sergey I. Moiseev, Anna Dmoszynska, Philippe Solal-Celigny, Krzysztof Warzocha, Javier Loscertales, John Catalano, Boris V. Afanasiev, Loree Larratt, Viktor A. Rossiev, Isabelle Bence-Bruckler, Christian H. Geisler, Marco Montillo, Michael K. Wenger, Martin Weisser
Journal: Blood
Blood (2010) 116 (20): 4212–4222.
https://doi.org/10.1182/blood-2010-03-272765
Published: 2010
Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD
Journal: Blood
Blood (2009) 114 (22): 2338.
https://doi.org/10.1182/blood.V114.22.2338.2338
Published: 2009
Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD
Journal: Blood
Blood (2008) 112 (11): lba-1.
https://doi.org/10.1182/blood.V112.11.lba-1.lba-1
Published: 2008
Journal Articles

Multicenter Experience of High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT) in Multiple Sclerosis (MS) Patients.

Yury L. Shevchenko, Andrei A. Novik, Alexey N. Kuznetcov, Boris V. Afanasiev, Igor A. Lisukov, Oleg A. Rykavicin, Alexandr A. Myasnikov, Tatiana I. Ionova, PhD, Sergey V. Shamanski, MD,PhD, Andrey D. Kulagin, MD,PhD, Olga A. Malysheva, MD, Nikolay I. Baziy, MD,PhD, Vladimir Y. Melnichenko, MD,PhD, Denis A. Fedorenko, MD,PhD, Inna V. Vereschagina, MD, Andrey E. Zdorov, MD, Anton V. Kishtovich, PhD, Roman A. Ivanov, PhD, Yury N. Fedotov, MD,PhD, Gary I. Gorodokin, MD
Journal: Blood
Blood (2006) 108 (11): 3072.
https://doi.org/10.1182/blood.V108.11.3072.3072
Published: 2006
Journal Articles

Treatment Outcomes in Multiple Sclerosis (MS) Patients after Early, Conventional and Salvage High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT).

Yury L. Shevchenko, Andrei A. Novik, Boris V. Afanasiev, Igor A. Lisukov, Tatiana I. Ionova, PhD, Andrei D. Kulagin, MD, Olga A. Malysheva, MD, Gennady N. Bisaga, MD, PhD, Vladimir J. Melnichenko, MD, PhD, Sergei V. Voloshin, MD, PhD, Denis A. Fedorenko, MD, PhD, Inna V. Vereschagina, MD, Anton V. Kishtovich, PhD, Yury N. Fedotov, MD, PhD, Gary I. Gorodokin, MD
Journal: Blood
Blood (2005) 106 (11): 5467.
https://doi.org/10.1182/blood.V106.11.5467.5467
Published: 2005
Journal Articles

Clinical and Quality of Life Outcomes in Patients with Multiple Sclerosis (MS) after High Dose Chemotherapy(HDCT)+Autologous Stem Cell Transplantation (ASCT).

Yury L. Shevchenko, Andri A. Novik, Boris V. Afanasiev, Igor A. Lisukov, Yury N. Fedotov, MD, Tatiana I. Ionova, PhD, Alexandr D. Kulagin, PhD, Olga A. Malysheva, MD, Gennadi N. Bisaga, PhD, Vladimir Y. Melnichenko, PhD, Lubov V. Chelombit, MD, Sergei V. Voloshin, PhD, Denis A. Fedorenko, PhD, Inna V. Vereschagina, MD, Anton V. Kishtovich, PhD
Journal: Blood
Blood (2004) 104 (11): 1875.
https://doi.org/10.1182/blood.V104.11.1875.1875
Published: 2004